These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 25941922)

  • 21. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
    Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
    Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
    Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
    Gong S; Chen Y; Meng F; Zhang Y; Li C; Zhang G; Huan W; Wu F
    Cell Prolif; 2018 Oct; 51(5):e12474. PubMed ID: 30069985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
    Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.
    Zhang M; Wang J; Yao R; Wang L
    Int J Gynecol Cancer; 2013 May; 23(4):659-66. PubMed ID: 23466567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Suppression of ATR reverses the cisplatin resistance in ovarian cancer SKOV3 cells].
    Yang Z; Sun C; Liu Y; Gong C; Chen G; Weng D
    Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):805-10. PubMed ID: 25620475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interfering EZH2 Expression Reverses the Cisplatin Resistance in Human Ovarian Cancer by Inhibiting Autophagy.
    Sun Y; Jin L; Liu JH; Sui YX; Han LL; Shen XL
    Cancer Biother Radiopharm; 2016 Sep; 31(7):246-52. PubMed ID: 27610467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
    Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
    Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.
    Ning J; Jiao Y; Xie X; Deng X; Zhang Y; Yang Y; Zhao C; Wang H; Gu K
    Oncol Rep; 2019 Feb; 41(2):1131-1139. PubMed ID: 30535472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing gene 1 in lung cancer cell A549/DDP].
    Gao Y; Su D; Ying L; Lv W; Ma S
    Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):846-9. PubMed ID: 20840811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Suppression of WWOX gene by RNA interference reverses platinum resistance acquired in SKOV3/SB cells].
    Liu YY; Li L; Li DR; Zhang W; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):854-8. PubMed ID: 19087571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MZF1 possesses a repressively regulatory function in ERCC1 expression.
    Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
    Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
    Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
    Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of circBIRC6 targeting miR-367-3p on cisplatin resistance of ovarian cancer cells].
    Zhang J; Bai HJ
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1062-1068. PubMed ID: 34695896
    [No Abstract]   [Full Text] [Related]  

  • 39. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
    Zhang TM
    Chemotherapy; 2019; 64(3):119-128. PubMed ID: 31661694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.
    Li E; Hu Z; Sun Y; Zhou Q; Yang B; Zhang Z; Cao W
    Tumour Biol; 2016 Jun; 37(6):7843-52. PubMed ID: 26695152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.